Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

NCT01997333 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01997333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01997333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
August 7, 2018
Enrollment
327 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gpnmb over-expressing triple negative breast cancer